Early Warning System

EIB-20250741

TECHEU VD SALVIA (BIOTECH ACT)

Early Warning System

TECHEU VD SALVIA (BIOTECH ACT)

EIB-20250741

Quick Facts

Countries	Netherlands
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	C
Voting Date	2026-06-24
Borrower	Salvia BioElectronics BV
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	$ 28.39 million
Project Cost (USD)	$ 66.99 million

Project Description

According to the Bank’s website, the project supports research, development and clinical evaluation of an implantable neurostimulation device used as a treatment for patients suffering from chronic migraine and cluster headache.

The project supports the Research, Development and Innovation (RDI) activities of a medical technology company specialised in developing innovative neuromodulation solutions for chronic migraine and other severe headache disorders. Its technology aims to provide therapeutic options for conditions with significant unmet medical needs, thereby strengthening innovation in the field of bioelectronic medicine.

Early Warning System Project Analysis

According to the Environmental and Social Data Sheet, the project concerns investments in research and development for which no significant impact on the environment is expected.

Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have low residual ECS risks and impacts.

Investment Description

- European Investment Bank (EIB)

The purpose of the loan is to provide direct, equity type financing under the EIB's Venture Debt Instrument to support the research, development and innovation (RDI) activities of the company.

Private Actors Description

Salvia BioElectronics BV is a clinical-stage medical device company based in Eindhoven, Netherlands, developing bioelectronic neuromodulation therapy for resistant migraine and chronic cluster headache. It is led by Chief Executive Officer Hubert Martens.

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Salvia Bioelectronics BV	Client	-

Contact Information

No contacts available at the time of disclosure.

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces

Bank Documents

- 26/06/2026 ESDS-TECHEU VD SALVIA (BIOTECH ACT)

Other Related Projects

- EIB-20230791 THEMATIC INNOVATION (INVESTEU VD) LE II